the evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries...
TRANSCRIPT
![Page 1: The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented](https://reader036.vdocument.in/reader036/viewer/2022082917/55190ebf5503464a428b4836/html5/thumbnails/1.jpg)
The evolution of generic medicine market share in the pharmaceutical retail sector of 21
countries between 1999 and 2009: a time series analysis
Presented by: Warren A. Kaplan 1
Co-authors: Veronika J. Wirtz2, Dennis Ross-Degnan3, Peter Stephens4
1 Center for Global Health & Development, Boston University, USA
2 Center for Health Systems Research, National Institute of Public Health, Mexico
3 Harvard Medical School and Harvard Pilgrim Health Care Institute
4 IMS Health, UK
![Page 2: The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented](https://reader036.vdocument.in/reader036/viewer/2022082917/55190ebf5503464a428b4836/html5/thumbnails/2.jpg)
Objectives
1. Investigate the retail, private sector market share by volume of generic medicines in various countries since 1999, data provided by IMS-Health.
– GLOBALLY, aggregated by regions;– REGIONALLY: Latin America/Caribbean, Asia and Africa– COUNTRY-SPECIFIC-selected countries
2. Investigate the retail, private sectormarket share by volume of selected tracer medicines since 2000, data provided by IMS-Health.
– AS INDIVIDUAL “TRACER” MEDICINES: simvastatin, omeprazole
3. Determine which level of analysis (global, regional, country, and/or tracer) best might provide retrospective and/or prospective data for decision-makers to evaluate existing and future pro-generic medicine policies .
![Page 3: The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented](https://reader036.vdocument.in/reader036/viewer/2022082917/55190ebf5503464a428b4836/html5/thumbnails/3.jpg)
Methods• Data obtained from IMS Health• PRIVATE SECTOR RETAIL volume data (i.e. number of pills/units)-excluding
vitamins and insulin– Latin America/Caribbean: Argentina, Brazil, Chile, Colombia, Dominican
Republic, Ecuador, Mexico, Peru, Uruguay, Venezuela, – Asia/Pacific: Bangladesh, Pakistan, Philippines, Thailand, – Africa: Morocco, Tunisia, Egypt, Jordan, South Africa– United States
• Branded Generic: Brand names marketed by a company without permission (license) from the originator
• INN generic: Sold by any company under the INN name
• “Generic(s)”: Branded + INN generics
• Total Market: Branded + INN+ Originator
![Page 4: The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented](https://reader036.vdocument.in/reader036/viewer/2022082917/55190ebf5503464a428b4836/html5/thumbnails/4.jpg)
Overall, market share of generics has increased; More in LAC than other places
![Page 5: The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented](https://reader036.vdocument.in/reader036/viewer/2022082917/55190ebf5503464a428b4836/html5/thumbnails/5.jpg)
By region, branded generic and INN generic market shares are divergent
![Page 6: The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented](https://reader036.vdocument.in/reader036/viewer/2022082917/55190ebf5503464a428b4836/html5/thumbnails/6.jpg)
In selected Countries: Generic market share is increasing over time but at varying rates
![Page 7: The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented](https://reader036.vdocument.in/reader036/viewer/2022082917/55190ebf5503464a428b4836/html5/thumbnails/7.jpg)
Generic Simvastatin 20mg: Effect of patent expiration U.S. (First patent expired 12/2005)
Worldwide: (First patent would have expired in 2001)
![Page 8: The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented](https://reader036.vdocument.in/reader036/viewer/2022082917/55190ebf5503464a428b4836/html5/thumbnails/8.jpg)
Generic Simvastatin 20mg :Even assuming a patent in Jordan/Egypt, why no
‘uptake’ after 2001?
![Page 9: The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented](https://reader036.vdocument.in/reader036/viewer/2022082917/55190ebf5503464a428b4836/html5/thumbnails/9.jpg)
Omeprazole patent expired in Mexico in 1999 & in the U.S.A. in 2001/NOT patented in other listed countries
What is holding back ‘uptake’ in Mexico?Why the lag in the Philippines?
![Page 10: The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented](https://reader036.vdocument.in/reader036/viewer/2022082917/55190ebf5503464a428b4836/html5/thumbnails/10.jpg)
Conclusions
• In general, global volume share of generic medicines has increased over the last decade; substantial differences exist by country and region in total generic marked share as well as branded vs. unbranded generics;
• The large increase in generic market share in LAC might be a result of more comprehensive pro-generic policies;
• Retail volume and patent data for individual medicines could provide an important tool for pharmaceutical policy evaluation:– Serve as a retrospective policy evaluator for decision-makers ( interrupted
time series)
– Serve as a prospective means to monitor policy impact in each country (trend analysis).